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Abstract 
Background: Pioglitazone is an oral antidiabetic drug with multiple pleiotropic actions. Recent clinical trials have 
demonstrated that treatment with pioglitazone reduces cardiovascular risk in patients who have had an ischemic 
stroke. We examined the secondary preventive effects of pioglitazone in acute ischemic stroke patients with diabetes 
mellitus (DM) based on nationwide real‑world data.
Methods: A nested case–control study was conducted with data from the National Health Insurance Service‑
National Sample Cohort in Korea. Study subjects were diabetic patients admitted for acute ischemic stroke (ICD‑10 
code; I63) between 2002 and 2013. Cases were defined as patients who suffered from composites of recurrent stroke 
(I60–63), myocardial infarction (I21), or all‑cause mortality after ischemic stroke. Controls were selected by incidence 
density sampling. Three controls were matched to each case for sex, age, treatment with insulin, and oral antidiabetic 
medications, with the exception of pioglitazone. Medication history after ischemic stroke was obtained by accessing 
the prescription records. In the matched dataset, conditional logistic regression analysis was performed with adjust‑
ments for hypertension, atrial fibrillation, prior myocardial infarction, and treatment with oral antithrombotics and 
statins.
Results: From the patients with acute ischemic stroke and DM, 1150 cases with primary outcomes were matched to 
3450 controls. In the matched analysis, treatment with pioglitazone was significantly associated with a lower cardio‑
vascular risk (adjusted OR [95% CI], 0.43 [0.23–0.83]).
Conclusions: In this nested case–control study using real‑world data, treatment with pioglitazone exhibited signifi‑
cant cardiovascular preventive effect in diabetic patients with acute ischemic stroke.
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Background
Stroke is the major cause of death and long-term dis-
ability worldwide [1]. Even with advances in modern 
medicine, stroke survivors have a greater risk of recur-
rent stroke and cardiovascular disease [2]. Recurrent 
events are more likely to be more disabling or fatal than 
the first event [3]. Diabetes mellitus (DM) is a common 
and well-established risk factor for stroke. Stroke patients 
with DM have a poor short- and long-term prognosis 
compared with non-diabetic stroke patients [4]. For dia-
betic stroke patients at high risk, effective cardiovascular 
preventive strategies remain a major clinical challenge. 
Pioglitazone is an oral antidiabetic medication belong-
ing to the drug class known as thiazolidinediones, and 
it acts as an agonist of the peroxisome proliferator-acti-
vated receptor γ (PPARγ). In addition to lowering serum 
glucose, pioglitazone has several pleiotropic effects, 
including reducing insulin resistance, inducing vascu-
lar inflammation, and improving endothelial dysfunc-
tion and dyslipidemia, which may lead to cardiovascular 
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protection [5]. Two large randomized trials have sug-
gested that treatment with pioglitazone reduces cardio-
vascular risk in patients with DM or insulin resistance 
who had suffered from an ischemic stroke or a tran-
sient ischemic attack (TIA) [6, 7]. In real-world data, the 
impact of pioglitazone may vary depending on different 
clinical characteristics of patients and interaction with 
other antidiabetic medications. Furthermore, the cardio-
vascular preventive effect of pioglitazone in Asian stroke 
survivors are not well known [8]. The aim of this study 
is to evaluate the cardiovascular effect of pioglitazone in 
acute ischemic stroke patients with DM using nationwide 
health claims data in Korea.
Methods
Study design and data source
We conducted a nested case–control study using the 
National Health Insurance Service-National Sample 
Cohort (NHIS-NSC) in Korea [9]. All Koreans are eli-
gible for and required to have universal health coverage 
under the NHIS. The NHIS-NSC consisted of 1,025,340 
participants who were selected from the NHIS database 
in 2002 using a stratified random sampling method based 
on sex, age, and household income level (2.2% of the total 
eligible Korean population in 2002). The NHIS-NSC 
database contains health insurance claims for hospital 
visits, medical procedures, prescription records (name, 
dose, duration, and date), clinical diagnoses, and clini-
cal characteristics including sex, age, household income, 
and death statistics. Diagnoses from each hospital visit 
were recorded according to the International Statistical 
Classification of Diseases, 10th revision (ICD-10). The 
NHIS-NSC data were fully anonymized in order to pro-
tect privacy. Due to the nature of a retrospective study 
with anonymized data, this study was approved and the 
requirement for informed consent was waived by the 
Institutional Review Board of Bundang CHA Medical 
Center (CHAMC 2018-12-032).
Study subjects
We established a cohort of patients aged ≥ 20  years old 
with DM and acute ischemic stroke, defined as hospitali-
zation (admission or emergency department visit) with a 
primary diagnosis of ischemic stroke (I63) between 2002 
and 2013. We only included patients who had undergone 
brain CT or MRI during hospitalization because of the 
assumption that those with acute ischemic stroke should 
undergo brain imaging [10]. The index date of the cohort 
was the starting date of hospitalization. The presence of 
DM is defined as the presence of ICD-10 codes (E08–11, 
E13–14) and at least one prescription of antidiabetic 
medication with diagnosis before or upon hospitaliza-
tion. Based on the health claims data of the NHIS-NSC, 
enrolled patients were followed up until the development 
of a primary outcome, the loss of eligibility for NHIS, 
death, or the study end date (Dec 31, 2013). Patients 
followed up for < 1  month were excluded. To avoid the 
confounding effect of rosiglitazone, another drug of the 
thiazolidinedione class withdrawn from the Korea’s mar-
ket in 2010 due to concerns of its increased cardiovascu-
lar risk, we excluded patients who had been exposed to 
rosiglitazone for ≥ 1 month during the study period.
Clinical outcomes
The primary outcome was a composite of recurrent 
stroke, myocardial infarction (MI), and all-cause death, 
whichever one occurred earliest. Patients were diagnosed 
with recurrent stroke if they were re-hospitalized with a 
primary diagnosis of I60–63 and underwent a brain CT 
or an MRI during their hospital visit. MI was defined as 
hospitalization with a primary diagnosis of I21. The diag-
nostic accuracy of I60–I63 for stroke in the NHIS has 
been reported to be over 80% in prior validation studies 
[11, 12]. The accuracy of I21 for MI in the NHIS has been 
reported to be 73–93% [13, 14]. Death statistics in stroke 
patients are considered to be reliable [15].
Selection of cases and controls
To construct a nested case–control study, we defined 
cases as patients who suffered from the primary outcome 
during the follow-up period. For each case, we sampled 
3 controls with replacement from the cohort, who were 
required to be event-free and at risk on the date of the 
primary outcome of their matched case, by incidence 
density sampling. Controls were required to be of the 
same sex and age as their matched case and to be taking 
the same medications at the time of case occurrence, that 
is, insulin and oral antidiabetic drugs, with the exception 
of pioglitazone.
Covariates
For baseline characteristics, we collected data on sex, age, 
and risk factors at index stroke. The presence of hyper-
tension (I10–15), atrial fibrillation (I48), and prior MI 
(I21) was defined by the diagnostic code of ICD-10 in the 
NHIS-NSC before or at hospitalization of index stroke. 
Hypertension was considered relevant only if the subject 
was prescribed antihypertensive drugs (calcium-channel 
blockers, angiotensin-converting enzyme inhibitors, 
angiotensin-receptor blockers, diuretics, and beta-block-
ers) with the diagnostic code [45].
Assessment of medications
We collected prescription records of pioglitazone, other 
oral antidiabetic medications (sulfonylurea, biguanide, 
dipeptidyl peptidase-4 inhibitor, and alpha-glucosidase 
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inhibitor), and insulin during the study period. Treat-
ment with oral antithrombotics (antiplatelet or anticoag-
ulant: aspirin, clopidogrel, ticlopidine, triflusal, cilostazol, 
warfarin, rivaroxaban, apixaban, and dabigatran) and 
statins (atorvastatin, fluvastatin, lovastatin, pitavasta-
tin, pravastatin, rosuvastatin, and simvastatin) was also 
evaluated based on prescription records. Sodium-glu-
cose co-transporter-2 inhibitors and edoxaban were not 
available in Korea during the study period. At times of 
primary outcomes in cases and matched controls, treat-
ment with these oral medications was determined by 
exposure within the past 30  days. Because the duration 
of treatment with insulin could not be directly obtained 
from prescription records in the NHIS-NSC (example of 
insulin prescription record: [regular insulin, 100 U/mL, 
10 mL Vial] × 2 on May 9, 2011), unlike oral medications, 
treatment with insulin was determined by the presence of 
insulin prescriptions within the past 90 days.
Statistical analyses
To estimate the odds ratio (OR) for primary outcomes 
with pioglitazone treatment, we performed conditional 
logistic regression with the matched case–control groups. 
As covariates, the presence of hypertension, atrial fibril-
lation, prior MI, treatment with oral antithrombotics, 
and statins were adjusted in the multivariate model. Data 
management and statistical analyses were performed 
with the SAS statistical software package, version 9.4 
(SAS Institute Inc., Cary, NC, USA) and R software, ver-
sion 3.4.3 (The R Foundation for Statistical Computing, 
Vienna, Austria; http://www.R-proje ct.org/). A two-sided 
p value of < 0.05 was considered statistically significant.
Results
In the NHIS-NSC, there were 12,503 patients with acute 
ischemic stroke (Fig.  1). In accordance with the inclu-
sion and exclusion criteria, we constructed a cohort 
of 3297 patients with acute ischemic stroke and DM. 
The mean post-stroke follow-up period of patients was 
3.1 ± 2.5  years (mean ± standard deviation). During the 
post-stroke follow-up period, there were 1428 patients 
who suffered from a primary outcome. To construct a 
nested case–control study, we randomly selected 3 con-
trols with replacement who were event-free and matched 
each one with a case having a primary outcome. After the 
matching process, we finally included 1150 patients with 
primary outcomes as cases and 3450 patients without 
primary outcomes as controls. Figure 1 displays the flow 
diagram for the case and control selection process with a 
nested case–control design.
Clinical characteristics of the selected cases and con-
trols are shown in Table  1. Due to the matching pro-
cess, there were no differences between the cases and 
the controls in sex, age, and treatment with antidiabetic 
medications (sulfonylurea, biguanide, dipeptidyl pepti-
dase-4 inhibitor, alpha-glucosidase inhibitor, and insu-
lin) except pioglitazone. Treatment with pioglitazone 
was more frequent in cases compared to controls (2.1% 
vs 1.0%). When we performed conditional logistic regres-
sion adjusted for hypertension, atrial fibrillation, prior 
MI, and treatment with oral antithrombotics and statins 
(Fig.  2), we found that treatment with pioglitazone was 
significantly associated with a lower risk of having a pri-
mary outcome (adjusted OR 0.43, 95% CI [0.23–0.83], 
p = 0.011). Along with pioglitazone, treatment with 
antithrombotics (adjusted OR 0.73, 95% CI [0.62–0.86]) 
and statins (adjusted OR 0.64, 95% CI [0.55–0.76]) 
showed significant cardiovascular preventive effects in 
acute ischemic stroke patients with DM.
Secondary analysis for individual outcome
Among the 1150 cases with primary outcomes, the num-
ber of patients with recurrent stroke, MI and all-cause 
death was 428, 50, and 672, respectively. We performed a 
conditional logistic regression analysis for the three sub-
groups consisting of cases with the individual outcome 
and matched controls (Table 2). In the secondary analy-
sis, treatment with pioglitazone was significantly associ-
ated with reduced risk for all-cause death.
Analysis considering burden of antidiabetic medications
In this nested case–control design matched for oral anti-
diabetic medications other than pioglitazone, there is a 
potential concern that the beneficial effect of pioglita-
zone may reflect more aggressive treatment with combi-
nations of antidiabetic treatments, rather than the class 
effect of pioglitazone (the difference in risk between 
biguanide and biguanide plus pioglitazone may be due to 
the higher medication burden, rather than pioglitazone 
itself ). To evaluate this possibility, we reconstructed a 
new nested case–control model in which each case was 
matched with 3 controls for sex, age, treatment with 
insulin, and the number of oral antidiabetic medications 
taken, including pioglitazone. In this model, cases and 
matched controls were prescribed the same number of 
oral antidiabetic medications (a patient taking biguanide 
plus pioglitazone could be matched with a patient taking 
biguanide plus sulfonylurea or any other combination of 
two classes of oral antidiabetic drugs). The median num-
ber of oral antidiabetic medications taken in both cases 
and controls was 1 [0–2] (median [interquartile range]). 
In the model in which cases were matched for the num-
ber of oral antidiabetic medications taken, the preventive 
effect of pioglitazone was also significant (adjusted OR 
0.40, 95% CI [0.20–0.83], p = 0.013).




(admission or emergency department 
visit with primary diagnosis of ‘I63’ 
& brain CT or MRI)
in 2002–2013
No diabetes mellitus (N=8,593)
N=12,503
Acute ischemic stroke with diabetes 
mellitus 
N=3,297
Age < 20 (N=11)
Followed up <1 month (N=507)
patients with primary outcome
N=1,428
plus
patients without primary outcome
N=1,869
1,150 cases with primary outcome
Exposure to rosiglitazone ≥1 month 
(N=95)
3,450 controls without primary 
outcome
For each case, 3 controls are matched 
(1:3) on sex, age, treatment of 
antidiabetic medications except 
pioglitazone. Controls are selected
with replacement from all persons at 
risk at the failure time of matched case.
Fig. 1 Flow diagram for the selection of cases and controls in a nested case–control study design. NHIS‑NSC the National Health Insurance 
Service‑National Sample Cohort in Korea
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Event‑free survival curve
To help understand the effect of pioglitazone, we illus-
trate an event-free survival plot according to treatment 
with pioglitazone based on the full cohort of patients 
with acute ischemic stroke and DM (N = 3297, Fig.  1). 
Accounting the nature of time-dependent variable of 
treatment with pioglitazone during follow-up period in 
the cohort, estimated event-free survival is visualized 
using the method of Simon and Makuch [16, 17]. When 
we compared the survival curves by the Mantel–Byar 
test, there is a significantly reduced risk for the primary 
outcome with pioglitazone (Fig. 3) [18].
Discussion
In this nested case–control study using nationwide 
health insurance claims data, treatment with piogl-
itazone was significantly associated with a lower risk 
of a primary outcome in diabetic patients with acute 
ischemic stroke. This finding is in line with prior studies 
reporting on the protective role of pioglitazone against 
cardiovascular disease. Treatment with pioglitazone, 
an antidiabetic medication currently available, may 
further reduce the residual cardiovascular risk in high-
risk patients with prior stroke and DM. In addition, we 
Table 1 Characteristics of cases and matched controls
Cases and controls (1:3) are matched for same sex, age, and treatment with sulfonylurea, biguanide, dipeptidyl peptidase 4 inhibitor, alpha-glucosidase inhibitor, and 
insulin
Crude OR (odds ratio), 95% CI (confidence interval) and p values are derived from conditional logistic regression analyses
a Antithrombotics include aspirin, clopidogrel, ticlopidine, triflusal, cilostazol, warfarin, rivaroxaban, apixaban, and dabigatran
Variables Cases (N = 1150) Controls (N = 3450) Crude OR [95% CI] p
Sex, male 578 (50.3) 1734 (50.3) –
Age 70–74 [65–69; 75–79] 70–74 [65–69; 75–79] –
Hypertension 1039 (90.3) 3005 (87.1) 1.40 [1.12–1.75] 0.003
Atrial fibrillation 184 (16.0) 398 (11.5) 1.49 [1.22–1.80] < 0.001
Prior myocardial infarction 140 (12.2) 358 (10.4) 1.20 [0.97–1.48] 0.088
Use of medications
 Antithromboticsa 713 (62.0) 2391 (69.3) 0.68 [0.58–0.79] < 0.001
 Statins 276 (24.0) 1156 (33.5) 0.61 [0.52–0.71] < 0.001
 Sulfonylurea 411 (35.7) 1233 (35.7) –
 Biguanide 379 (33.0) 1137 (33.0) –
 Dipeptidyl peptidase 4 inhibitor 34 (3.0) 102 (3.0) –
 Alpha‑glucosidase inhibitor 86 (7.5) 258 (7.5)
 Pioglitazone 11 (1.0) 74 (2.1) 0.44 [0.23–0.83] 0.012





   antithrombotics
   statins






















0 0.5 1 1.5 2
adjusted OR [95% CI]
Fig. 2 Risk factors for primary outcomes in the patients with acute ischemic stroke and diabetes mellitus. Primary outcome is defined as 
composites of recurrent stroke, myocardial infarction, or all‑cause death after acute ischemic stroke. Cases and controls are matched for same sex, 
age, and treatment with sulfonylurea, biguanide, dipeptidyl peptidase 4 inhibitor, alpha‑glucosidase inhibitor, and insulin. Adjusted OR (odds ratio), 
95% CI (confidence interval) and p value are derived from conditional logistic regression analyses, which included the listed variables
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demonstrated the applicability of pioglitazone’s preven-
tive effect in treating Asian stroke patients.
Prior clinical trials for cardiovascular effect of pioglitazone
There have been two large randomized clinical trials 
evaluating the cardiovascular preventive effects of piogl-
itazone. The PROspective pioglitAzone Clinical Trial In 
macroVascular Events (PROactive) study was a rand-
omized trial which investigated the secondary preven-
tive effect of pioglitazone in 5238 patients with type 2 
diabetes and macrovascular disease [19]. Compared with 
our study, which included patients with acute ischemic 
stroke, the PROactive study included patients who had 
been more than 6 months since the onset of MI or stroke 
before study entry. Although the PROactive study failed 
to show a significant benefit of pioglitazone from primary 
outcome analysis, there was a significantly reduced rate 
of fatal or nonfatal stroke with pioglitazone treatment in 
a subgroup analysis of patients with prior stroke (haz-
ard ratio (HR) 0.53, 95% CI 0.34–0.85, p = 0.009) [7]. In 
subgroups without prior stroke, there was no signifi-
cant preventive effect of pioglitazone on the develop-
ment of stroke (HR 1.06; 95% CI 0.73–1.52, p = 0.767). 
The Insulin Resistance Intervention After Stroke (IRIS) 
trial, performed more recently, was a randomized clini-
cal trial based on the hypothesis that pioglitazone may 
reduce cardiovascular risk in non-diabetic patients with 
recent ischemic stroke or TIA (within 6  months) and 
insulin resistance [6]. It is well established that people 
with insulin resistance are at a higher risk of cardiovas-
cular disease, even if non-diabetic, and insulin resistance 
is common in ischemic stroke patients [20]. Pioglitazone 
has been shown to be effective in improving both gly-
cemic control and insulin-resistance [21]. The IRIS trial 
showed that treatment with pioglitazone can reduce the 
risk of both acute coronary events and ischemic stroke 
in insulin resistant patients who had a recent ischemic 
stroke or TIA [22, 23]. In this IRIS trial, primary out-
comes of fatal or non-fatal stroke or myocardial infarc-
tion had occurred in 9.0% of the pioglitazone group and 
11.8% of the placebo group by 4.8  years into the study 
period (HR 0.76, 95% CI 0.62–0.93, p = 0.007). The Jun-
tendo Stroke Prevention study in Insulin Resistance and 
Impaired glucose Tolerance (J-SPIRIT) study was another 
randomized trial consisting of 120 patients with impaired 
glucose tolerance or newly-diagnosed DM in Japan who 
had experienced a non-disabling ischemic stroke or a 
TIA [24]. Over a median follow-up period of 2.8  years, 
treatment with pioglitazone was associated with a lower 
risk of recurrent stroke (HR 0.62, 95% CI 0.13–2.25, 
p = 0.49), although the difference was not statistically 
significant and the trial was underpowered to evaluate 
the effect of pioglitazone. A meta-analysis of the above 
three trials demonstrated that treatment with pioglita-
zone in stroke patients with insulin resistance, prediabe-
tes, and DM was associated with a significantly lower risk 
of recurrent stroke (HR 0.68, 95% CI 0.50–0.92, p = 0.01) 
and major vascular events (HR 0.75, 95% CI 0.64–0.87, 
p < 0.01) [25].
Meta‑analysis and observational studies for cardiovascular 
effect of pioglitazone
Similarly, a meta-analysis of ten randomized controlled 
trials with patients with cardiovascular disease found a 
significantly reduced risk for recurrent major adverse 
cardiovascular events with pioglitazone treatment (rela-
tive risk 0.74, 95% CI 0.60–0.92) [26]. Another meta-
analysis of nine randomized trials found that treatment 
with pioglitazone was associated with a lower risk of 
Table 2 Secondary analysis for  individual outcome 
according to treatment with pioglitazone
For each case, three controls are matched for same sex, age, and treatment with 
sulfonylurea, biguanide, dipeptidyl peptidase 4 inhibitor, alpha-glucosidase 
inhibitor, and insulin. Adjusted OR (odds ratio) and 95% CI (confidence interval) 
for ‘treatment with pioglitazone’ are derived from conditional logistic regression 
analyses with adjustments for hypertension, atrial fibrillation, prior myocardial 
infarction, treatment with antithrombotics and statins





Recurrent stroke 428 0.70 [0.31–1.61]
Myocardial infarction 50 NAa
All‑cause death 672 0.27 [0.09–0.79]






















Fig. 3 Event‑free survival plot according to treatment with 
pioglitazone. The plot illustrates an estimated event‑free survival 
curve according to treatment with pioglitazone (defined as exposure 
within the past 30 days) during the followed‑up period after acute 
ischemic stroke. p value is obtained from the Mantel–Byar test which 
compares survival curves by treatment with pioglitazone
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cardiovascular events in patients with pre-diabetes or 
insulin resistance (relative risk 0.77, 95% CI 0.64–0.93) 
and diabetes (relative risk 0.83, 95% CI 0.72–0.97) [27]. 
In addition to the data from these randomized trials, 
the preventive effect of pioglitazone on cardiovascular 
disease was also demonstrated in observational stud-
ies [28, 29]. From real-world data based on Taiwan’s 
National Health Insurance Research Database of type 2 
DM patients newly prescribed oral antidiabetic medica-
tions, pioglitazone users were at a significantly lower risk 
of cardiovascular events than non-pioglitazone users 
(adjusted HR 0.61, 95% CI 0.50–0.75) [30].
Magnitude of the cardiovascular risk reduction 
by pioglitazone
In line with previous reports, our findings provide real-
world evidence of the preventive effect of pioglitazone 
on cardiovascular disease in patients with acute ischemic 
stroke and DM. Based on our data, the magnitude of the 
risk reduction by pioglitazone (adjusted OR 0.43) seemed 
to be greater than those determined in prior randomized 
trials (HR 0.53 in PROactive, HR 0.76 in IRIS). The more 
favorable effect observed in our study may originate from 
the differences in the clinical characteristics of the study 
population. Unlike randomized trials, real-world data 
included heterogenous patients with multiple comor-
bidities. Compared with the PROactive study (which 
included diabetic patients with myocardial infarction or 
stroke > 6  months before study entry) or the IRIS study 
(which included patients with ischemic stroke or TIA 
with insulin resistance), the diabetic patients hospital-
ized for acute ischemic stroke in this study may receive 
a greater benefit from pioglitazone with respect to their 
underlying higher risk [31]. While the main data reported 
in the PROactive and IRIS trials were based on the ‘inten-
tion-to-treat’ analysis regardless of the compliance to the 
treatment, current study evaluated the treatment effect 
of pioglitazone based on the actual prescription records 
during the study period. In the post hoc analysis of IRIS 
trial regarding adherence to pioglitazone (‘on-treatment 
analysis’), the risk reduction in those with good adher-
ence was more greater (HR [95% CI] were 0.57 [0.39–
0.84] for stroke/MI compared to placebo) than the 
estimation by the ‘intention-to-treat’ analysis [32].
Cardiovascular protective mechanisms of pioglitazone
Currently, the exact mechanism of how pioglitazone 
reduces cardiovascular risk is still unclear. Pioglitazone 
is principally a PPARγ agonist and partially an activator 
of PPARα, whose actions improve glycemic control and 
insulin sensitivity. Pioglitazone, through its PPARγ ago-
nist actions, regulates gene expression in multiple insu-
lin-sensitive tissues, lipid-metabolism, and inflammation 
[33–36]. Independent of glycemic control, pioglitazone 
has multiple positive effects on fat distribution, coagu-
lation, thrombosis, lipid and protein composition, and 
vascular inflammation [6]. Upon treatment with piogl-
itazone, overall favorable changes are noted, including 
decreases in blood pressure, triglycerides, and C-reactive 
protein and increases in insulin sensitivity, high-density 
lipoprotein-cholesterol, adiponectin, and apolipopro-
tein A–I, as well as regulation of the balance between 
regulatory and effector T cells [37–41]. Treatment with 
pioglitazone reduced the oxidation of high-density lipo-
proteins, but not low-density lipoprotein in patients with 
type 2 diabetic mellitus [42]. Pioglitazone may contrib-
ute to the attenuation and stabilization of atherosclerotic 
plaque inflammation, alteration of atherosclerotic core 
composition, reduction of the necrotic core, and preven-
tion of intimal hyperplasia after coronary stent implan-
tation [22, 27, 43–46]. Treatment with pioglitazone can 
slow the progression of carotid intima-media thicken-
ing and improve endothelial function [37, 47, 48]. The 
beneficial effects of pioglitazone are apparent regardless 
of the use of other antidiabetic medications or insulin 
[19]. Although we were unable to identify the underlying 
mechanism of action of pioglitazone, our finding suggests 
that improvement in insulin resistance and high pleio-
tropic potency of pioglitazone could contribute to reduc-
ing residual cardiovascular risk in diabetic patients with 
acute ischemic stroke. Further study is needed to eluci-
date even more of the promising effects of pioglitazone 
on prevention of cardiovascular disease.
Strength and limitation
This study had strengths and limitations. By using nation-
wide health insurance claims data, we could evaluate the 
long-term, real-world prognosis of acute ischemic stroke 
patients with DM according to the treatment with piogl-
itazone. Unlike well-designed clinical trials, changes in 
drug medications and non-adherence to medications 
are common in clinical practice. Because the NHIS in 
Korea is a single payer insurer, we were able to access 
detailed prescription data for treatment with pioglita-
zone and other antidiabetic medications throughout the 
post-stroke period. For proper control of serum glucose, 
DM patients frequently need to receive multiple classes 
of antidiabetic medications. Concomitant use of other 
classes of antidiabetic medications could act as a bar-
rier to evaluate the effect of the individual medications. 
To minimalize the influence of concomitant antidiabetic 
medications, we conducted a nested case–control study 
which matched cases and controls according to their use 
of other antidiabetic medications. The significant reduc-
tion of primary outcomes observed in this matched data-
set points to the independent benefit of pioglitazone for 
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secondary prevention, regardless of concomitant anti-
diabetic medications. However, with the limitation of a 
retrospective study design, we should also consider the 
possibility of hidden bias between patients who received 
pioglitazone and those who did not. In this study, only 
a small portion of patients received pioglitazone, which 
could result in biased estimates. The low usage of piogl-
itazone may reflect the non-adherence to antidiabetic 
medications and the functional deficit of stroke patients. 
Nevertheless, the large portion of non-pioglitazone-
treated patients could be potential targets for effective 
risk reduction by treatment with pioglitazone.
Because the current study constructed matched data-
set for treatment with antidiabetic medications, we 
could not evaluate the potential effect of individual class 
except pioglitazone and various combinations of anti-
diabetic medications. Besides pioglitazone, other class 
of antidiabetic medications may provide various cardio-
vascular effects, not merely on the development of acute 
cardiovascular events. A nationwide cohort study from 
the Taiwan National Health Insurance Database dem-
onstrated that combinations of thiazolidinediones plus 
metformin and alpha-glucosidase inhibitors plus met-
formin were associated with a lower risk of major adverse 
cardiovascular event when compared with sulfonylurea 
plus metformin [49]. Another real world data from the 
Taiwan National Health Insurance Database showed 
that treatment with dipeptidyl peptidase-4 inhibitor was 
associated with a lower risk of new-onset atrial fibrilla-
tion which is the most common cause of cardioembolic 
stroke [50]. In a network analysis from 11 randomized 
controlled trials, gliclazide (a type of sulfonylureas) was 
the only medication that significantly reduced left ven-
tricular mass in type 2 diabetes [51]. Recent clinical trials 
have documented that treatment with glucagon-like pep-
tide-1 receptor agonists, which is not available during the 
current study period in Korea, can lead to marked risk 
reduction in major adverse cardiovascular events [52]. 
Overall, it is necessary to conduct more research to eval-
uate cardiovascular effect and action mechanism of the 
antidiabetic agents.
This study was performed with Asian stroke patients 
with DM. The individual characteristics of stroke patients 
and their responses to medication may differ with race 
and ethnicity [53]. In addition, our study did not pro-
vide data on the effect of pioglitazone in patients with-
out stroke. Therefore, our results should be interpreted 
with caution, and the general applicability of pioglita-
zone to different populations should be further evalu-
ated. There were also limitations of study from health 
claims data. Due to the lack of detailed clinical informa-
tion in health claims data, we could not collect data on 
the severity of index stroke, radiological findings, blood 
pressure, duration of diabetes mellitus, levels of glucose, 
Hemoglobin A1c and low-density lipoprotein, which are 
strong prognostic factors in stroke patients. The interac-
tion between pioglitazone and the risk factors needs to 
be further investigated. Although we were able to collect 
entire prescription records, there could have been gaps 
between prescriptions and actual patient intake of medi-
cations. Fortunately, prior studies showed a good corre-
lation between prescription records and actual intake of 
medications [54, 55]. The determination of outcomes was 
based on diagnostic codes in the health claims records. 
Although our method of determination of cardiovascular 
outcomes based on ICD-10 codes in the NHIS was vali-
dated and widely used, records of patients who did not 
visit the hospital or records containing entry errors may 
not have been captured [10].
Conclusions
This study based on nationwide real-world data demon-
strated the significant cardiovascular preventive effect 
of pioglitazone in diabetic patients with acute ischemic 
stroke. Pioglitazone is currently an available antidiabetic 
drug, and treatment with pioglitazone may be a promis-
ing strategy for reducing residual cardiovascular risk in 
patients with ischemic stroke and DM who are consid-
ered to be high-risk.
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